ÂÜÀòÂÒÂ×

Mel Hayes joined Fulcrum Therapeutics in September 2021 as chief commercial officer, offering more than 25 years of experience in development and management of commercialization strategies in a range of therapeutic areas including many rare and specialty diseases. At Fulcrum he is responsible for leading the company’s commercial strategies and operations, including marketing, sales, new product planning, business analytics, and patient engagement. Prior to Fulcrum, Mr. Hayes most recently served as global head commercial, vice president, rare blood disorders at Sanofi-Genzyme, where he led the commercial organization for hemophilia and complement assets. He also served as U.S. vice president hemophilia and global head, hematology rare blood disorders at Bioverativ (acquired by Sanofi-Genzyme). He was formerly global vice president, head of global marketing and launch excellence at Shire and was global vice president hemophilia at Baxalta (acquired by Shire). He also spent 10 years at Bayer and nine years at Bristol Myers Squibb in progressive leadership roles where he was responsible for launching products in diabetes, cardiovascular disease, neurology, rheumatology, multiple sclerosis and Parkinson’s disease. He earned dual bachelor’s degrees in business and communications from Southern Methodist University and an MBA from Columbia University.